CADTH Canadian drug expert committee recommendation: Siponimod (Mayzent -- Novartis Pharmaceuticals Canada Inc.) indication : secondary progressive multiple sclerosis
Siponimod has a Health Canada indication for the treatment of patients with SPMS with active disease evidenced by relapses or imaging features characteristic of multiple sclerosis inflammatory activity, to delay the progression of physical disability. Siponimod isa sphingosine 1-phosphate receptor m...
| Corporate Authors: | , |
|---|---|
| Format: | eBook |
| Language: | English |
| Published: |
Ottawa (ON)
Canadian Agency for Drugs and Technologies in Health
2020, July 2020
|
| Edition: | Version: 1.0 |
| Series: | CADTH common drug review
|
| Online Access: | |
| Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
| Summary: | Siponimod has a Health Canada indication for the treatment of patients with SPMS with active disease evidenced by relapses or imaging features characteristic of multiple sclerosis inflammatory activity, to delay the progression of physical disability. Siponimod isa sphingosine 1-phosphate receptor modulator and is available as a 0.25 mg or a 2 mg film-coated tablet. The dosage regimen recommended by the Health Canada includes a six-day titration period starting with 0.25 mg and progressing up to 1.25 mg on day 5 followed by a 2 mg maintenance dose starting on day 6. The recommended maintenance dose of sionimod is 2 mg taken once daily with or without food |
|---|---|
| Item Description: | "Final." |
| Physical Description: | 1 PDF file (9 pages) illustrations |